Gilead Sciences has announced topline results from a Phase 3 clinical trial (Study GS-US-334-...
Idenix Pharmaceuticals has filed patent infringement lawsuits against Gilead Sciences and/or...
An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is...
New research suggests that a shot every one to three months may someday give an alternative to the daily pills that some people take now to cut their risk of getting HIV.
Gilead Sciences said that sales of its hepatitis C pill Sovaldi totaled $139.4 million after the drug was approved in December, helping its fourth-quarter profit rise 4 percent.
Mylan Inc. has announced that its India-based subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.'s exclusive branded medicines business partner for India.
Gilead Sciences, Inc. today announced several promotions within the company’s senior management team.
The drug Sovaldi (sofosbuvir) is to be taken in combination with older medications to treat the main forms of hepatitis C, which is caused by a blood-borne virus. Left untreated, the disease can lead to liver failure, cirrhosis and cancer.
Gilead Sciences has announced that the FDA has approved the single tablet HIV-1 regimen Complera ® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen
U.S. health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences Inc. that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.
Gilead Sciences said that its third-quarter profit rose 17 percent on higher sales of its best-selling HIV drugs. Net income was $788.6 million, or 47 cents per share, in the July-September period, compared with $675.5 million, or 43 cents per share, for the third quarter of 2012.
FDA advisers on Friday unanimously voted in favor of a highly anticipated hepatitis C drug from Gilead Sciences that holds promise for millions of Americans infected with the liver-destroying virus. All 15 members of the FDA's panel of virus experts voted to recommend approval of Gilead's pill, sofosbuvir, to treat several forms of hepatitis C.
The Food and Drug Administration has issued a positive review for a highly anticipated hepatitis C drug from Gilead Sciences, saying the pill cures more patients in less time than currently available treatments. The agency posted its review of Gilead's sofosbuvir online ahead of a meeting Friday.
The Food and Drug Administration holds a public meeting this week to review two experimental medications from Johnson & Johnson and Gilead Sciences. The new drugs, if approved, could offer a quicker, more effective approach to eliminating hepatitis C, a blood-borne disease blamed for 15,000 deaths in the U.S. this year.
Following a recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences has announced that its Phase 3 study (Study 116) evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early.
The FDA has approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. It is a pill taken daily in combination with other antiretroviral drugs.
Shares of Gilead Sciences Inc. rose to all-time highs Friday after the company reported its first-quarter results and new trial data for two of its experimental hepatitis C drugs. THE SPARK: Gilead posted its quarterly results after the market closed Thursday. The company said its net income...
Gilead said sales of its two biggest-selling drugs, the HIV medicines Atripla and Truvada, both fell. But its total revenue increased because of stronger sales of other products, including other HIV drugs, its heart drug Letairis, angina treatment Ranexa, and growing sales of Stribild, a four-in-one HIV pill that was approved in August.
Gilead Sciences today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus (HCV) infection.
Idenix Pharmaceuticals Inc. shares sank Monday after the U.S. Patent and Trademark Office determined a competitor was the first to request a patent for a hepatitis therapy. The biopharmaceutical company said an appeals board decided that Idenix's patent application for compounds used to treat hepatitis C was filed after Gilead Pharmasset LLC's application.
Shares of Gilead Sciences Inc. moved higher Tuesday after the company reported more clinical trial data for an experimental HIV pill.Gilead had previously said the new pill, called TAF, worked about as well as the company's Stribild tablet in a mid-stage clinical trial, but had lower rates of side effects related to kidney problems and bone loss.
Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch SurveyMarch 4, 2013 7:59 am | News | Comments
More than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
Gilead Sciences, Inc. today announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread® (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.
Gilead Issues a Voluntary Recall of One Lot of Vistide® (Cidofovir Injection) Due to Presence of Particulate MatterFebruary 19, 2013 8:10 am | News | Comments
Gilead Sciences, Inc. has announced it is voluntarily recalling lot B120217A of Vistide ® (cidofovir injection) to the user level due to the presence of particulate matter found in some vials of this lot. Effects from intravenous injection of product with particulate matter can vary depending on the amount of particulate matter injected into the patient.
HIV drug maker Gilead Sciences Inc. said Monday that its fourth-quarter profit grew nearly 15 percent on higher sales of antiviral drugs, edging past analyst estimates. For the quarter ended Dec. 31 Gilead Sciences earned $762.5 million, or 47 cents per share, up from $665.1 million, or 43 cents per share, in the last quarter of 2011.
Gilead Sciences, Inc. and YM BioSciences Inc. announced today that the companies have signed a definitive agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash.
FOSTER CITY, Calif. (AP) — HIV drug maker Gilead Sciences Inc. said Monday that its board approved a two-for-one stock split that will take effect in January.
European Commission Approves Viread® for HIV-1 Infection in Children and Adolescents and for Chronic Hepatitis B in AdolescentsNovember 28, 2012 3:05 am | News | Comments
Gilead Sciences, Inc. has announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread® (tenofovir disoproxil fumarate).
- Page 1